Company Overview and News
VANCOUVER, BC / ACCESSWIRE / October 17, 2018 / BTU METALS CORP. ("BTU" or the "Company") (TSX-V: BTU) is pleased to announce it has entered into two agreements with arms-length vendors to acquire two strategic properties, both adjoining and contiguous to the south and south-west border of Great Bear Resources Corp.'s (GBR) Dixie Project located in the Red Lake District of Ontario.
Great Bear Resources (CVE:GBR) President and CEO Chris Taylor joined Steve Darling in the Proactive Investors Vancouver studios to highlight positive results from their Dixie Project.
2018-09-11 globenewswire - 1
TORONTO, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Rob McEwen, through his wholly owned company Evanachan Limited (“Evanachan”), and McEwen Mining Inc. (“MUX”) have subscribed today for 3,930,932 Units (the “Units”) of Great Bear Resources Ltd. (“GBR”) of 1020-800 West Pender Street, Vancouver, BC, V6C 2V6 at a price of $1.45 per Unit for an aggregate gross investment of $5,699,851.40. The subscriptions by Evanachan and MUX were made by way of private placement, which formed part of a larger offering by GBR on the same terms (the “Offering”).
MUX.RTWI GTBDF MUX GBR MUX
Coeur Mining made a move to buy a heap leach gold deposit in Nevada; Northern Star goes to Alaska for its next mine.
RIO RIO GTBDF KGI.DB NST FCX BFDRF GSV NSU BFD RTPPF MUX.RTWI RTNTF MUX GG KL SAND SSL SDDXF KGI MUX KGI.DB.A CDEUW NULGF SNXZF PSPGF NESRF CDE RIO GBR NHRNY
Back in June Jay Taylor's Gold, Energy & Tech Stocks newsletter published a nice write-up on a junior gold miner called Great Bear Resources (OTCPK:GTBDF), which included the following:
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET